Critical Review of the September 2026 CHMP Medicinal Product Recommendations

The European Medicines Agency has posted the monthly summary of opinions adopted by the Committee for Medicinal Products for Human Use at its 14–17 September 2026 session, and practitioners would do well to treat the headline framing with the same skepticism one applies to any dossier cleared by committee vote rather than independent re-analysis.

What the committee actually issued

According to the EMA release, the September CHMP session produced its standard slate of expert recommendations and safety evaluations on marketing authorisations across the European Union. No granular list of specific opinions, positive or negative, is reflected in the circulated summary; the agency has indicated only that the meeting outputs are now publicly available through its usual channels. For clinicians, that means the document of record remains the meeting highlights page itself, and any secondary characterisation of which compounds received a green light, a refusal, or a conditional nod should be sourced directly from the EMA rather than aggregated commentary.

Why the methodology deserves a second look

Olivia Brentwood, reviewing similar CHMP outputs for impasl.com readers, notes that monthly committee highlights are, by design, summaries rather than full assessment reports. The publicly available text tends to compress primary endpoints, confidence intervals, and contraindications into brief paragraph-form statements that obscure the statistical caveats a prescribing physician needs. A favourable opinion on a novel agent does not equate to robust efficacy data; the relevant question is whether the supporting trials were adequately powered, whether the chosen endpoints were clinically meaningful or surrogate, and whether the safety profile has been followed long enough to detect signals that phase II/III populations underrepresent. None of those distinctions are visible in a short committee summary.

Practitioners should also watch for the now-routine pattern in which conditional marketing authorisations are granted on the basis of immature data sets, with post-authorisation efficacy studies promised but not yet delivered. The September session is unlikely to break that pattern, and the meeting highlights are precisely the place where that trend gets laundered into clean-sounding approval language.

What to verify before acting on the highlights

Before any prescribing decision or formulary discussion is built on the September CHMP outputs, clinicians should pull the full Committee Referral / Assessment Report for each compound mentioned, confirm the indicated patient population against one's own roster, and cross-check the Risk Management Plan against contraindications relevant to comorbid populations. For independent practitioners building a therapeutics protocol, the prudent move is to wait for the European Public Assessment Report rather than rely on the meeting summary as a clinical reference.